SCHEMBL5132433

SCHEMBL5132433

O=CCN(C(=O)O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
GLA P06280 2/20 0.48
TSHR P16473 2/20 0.48
HTT P42858 3/20 0.47
NPSR1 Q6W5P4 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
PAX8 Q06710 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
POLB P06746 1/20 0.44
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.41
LTB4R2 Q9NPC1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14397791 0.84 ALDH1A1 (0.46) ALDH1A1GLATSHRHTTNPSR1
SCHEMBL27567536 0.84 ALDH1A1 (0.51) ALDH1A1GLATSHRHTTNPSR1
SCHEMBL7751622 0.82 ADRA2C (0.56) ALDH1A1GLATSHRHTTSMN1; SMN2
SCHEMBL10187754 0.82 KMT2A (0.37) ALDH1A1NPSR1NPC1RAB9AKMT2A
SCHEMBL14830960 0.82 CYP3A4 (0.45) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL27358125 0.82 ALDH1A1 (0.52) ALDH1A1GLATSHRHTTNPSR1
SCHEMBL946547 0.82 TSHR (0.53) ALDH1A1GLATSHRHTTNPSR1
SCHEMBL14397832 0.81 TP53 (0.50) ALDH1A1GLATSHRHTTNPSR1
SCHEMBL14397875 0.81 ALDH1A1 (0.43) ALDH1A1GLATSHRHTTNPSR1
SCHEMBL16718509 0.81 RAB9A (0.35) ALDH1A1GLATSHRHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
EP-2336105-B9 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL (JP) 2014-09-17 EP disclosed
EP-2336105-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL (JP) 2014-02-12 EP disclosed
US-8592454-B2 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-11-26 US disclosed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 ALDH1A1 399/4885GLA 4286/4885TSHR 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.